Ultramini abstract
The management of antiplatelet therapy resistance currently lacks clear outlines. This review summarizes the treatment options for patients found to have high residual platelet reactivity despite receiving the recommended anti-platelet agents. It also provides the cut-off points for platelet function tests differentiating anti-platelet therapy "responders" from "nonresponders".
The role of coronary artery bypass grafting (CABG) in the management of complex coronary artery disease has been validated through an unparalleled level of scrutiny. Improvement in patient outcomes nowadays relies on continued refinements of the surgical technique and modulation of adjuvant pharmacotherapy. Postoperative antiplatelet therapy (APT) is paramount in maintaining the revascularization benefit. Individual variability to APT, however, results in unpredictable platelet inhibition. Currently available platelet function tests (PFT) dichotomize patients into "responders" and "non-responders" based upon arbitrarily defined cut-off points. Not surprisingly, the incidence of APT resistance across the spectrum of PFTs is widely discrepant, underscoring the fact that single pathway descriptors of platelet aggregation fail to portray the complexity of the process. Thrombosis is the principal mode of failure of saphenous vein grafts (SVG) in the early postoperative period 1 . Reports on the increased incidence of SVG failure in patients experiencing antiplatelet agent resistance underscore the importance of recognizing this entity and intervening in a timely fashion. This review summarizes the various assay-dependent definitions of APT resistance, with their respective rates of occurrence. The clinical impact of on-therapy high residual platelet reactivity (hRPR) in the cardiac surgical arena is discussed. Finally, guidelines on individual tailoring of antiplatelet therapy in patients found to retain high on-therapy platelet reactivity are suggested herein.
Methods
The PUBMED database was searched using the following subject terms: "platelet function testing", "antiplatelet", "aspirin", "clopidogrel", "resistance" and "cardiac surgery".
Reference lists of identified publications were analyzed for additional linking studies. Priority was given to cohort studies and reviews.
Definition of anti-platelet therapy resistance
Aspirin is the most commonly used anti-platelet agent after CABG. Its use is associated with a 40% reduction in bypass graft occlusions 2 , with the benefit being most evident in saphenous vein grafts 3, 4 . The incidences of SVG graft occlusions within the first year, when the impact of thrombosis is greatest, range between 7.4% and 26% [5] [6] [7] . This angiographic outcome is accompanied by a 20%-30% reoccurrence of angina 8 and a 5.9% need for repeat revascularization within the first year 9 . The current guidelines on postoperative APT recommend the initiation of 100-325 mg of aspirin within 6 hours of surgery 10 . In patients unable to take aspirin, 75 mg of clopidogrel is the suggested alternative 10 .
The importance of prompt postoperative institution of aspirin is underscored by the fact that starting aspirin on the third postoperative day or later is unlikely to reflect favorably on graft patency 11, 12 . The one-size-fits all recommendation for perioperative APT in the current guidelines, however, disregards the individual response variability.
The term aspirin resistance denotes the drug's inability to effectively suppress cyclooxygenase 1 (COX-1) dependent thromboxane A2 (TxA2) production. Aspirin's failure to act on its pharmacological target originates from variable enteral absorption, COX-1 gene mutations, drug-drug interactions, patient non-compliance, accelerated post-cardiopulmonary bypass (CPB) platelet turnover and TxA2-independent platelet activation pathways 13, 14 . The prevalence of aspirin resistance varies widely in the literature, due to variable platelet agonists used in testing and different aspirin-related platelet function descriptors (Table 1) .
Clopidogrel is an inactive prodrug that undergoes extensive conversion into its active metabolite by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme 15 . [17] [18] [19] [20] [21] [22] . Antiplatelet agent response is best perceived as a continuous variable. The efficacy of APT, however, may be assessed in relation to cut-off points discriminating between "resistance" and "response", or by measuring the on-therapy percent platelet inhibition and comparing it to values obtained prior to APT. The drawback of the latter strategy is that it is affected by variability in baseline platelet reactivity. 
Clinical impact of anti-platelet therapy resistance
Aspirin-resistant TxA2 synthesis has been found to elevate the risk of stroke, myocardial infarction and cardiovascular death in patients with cardiovascular disease 25 . A graded increase in the aforementioned risk was observed with each increasing quartile of urinary 11-dehydro thromboxane B2 (UTxB2), which is a metabolic surrogate of TxA2
Investigators in the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) trial noted an alarming correlation between graft occlusion and antiplatelet therapy resistance (RR 3.6, 95% CI 2.5 to 6.9; P <0.001) 5 . Conversely, synergistic aspirin-and clopidogrel-induced platelet inhibition was found to predict SVG patency (RR 5.1, 95% CI 1.4 to 16.3; P <0.01) 5 . The link between SVG occlusion and platelet hyperreactivity on aspirin was reported as the secondary objective of the Reduction in Graft
Occlusion Rates (RIGOR) study 13 . A higher incidence of early SVG occlusion was found in patients taking aspirin who had increased levels of UTxB2 and shear-dependent platelet activation 13 .
Clopidogrel resistance has also been found to be clinically significant by several investigators. Adverse cardiovascular events adjudicated at 6-months were found to be more 30 . These observations again add credence to APT monitoring, as it may directly influence the preoperative discontinuation of clopidogrel and possibly lead to a revision of current guidelines.
Management options for antiplatelet agent resistance
With the problem of antiplatelet agent resistance lacking a clear outline and definition, it is not surprising that guidelines for its management remain to be formed. While a large proportion of the evidence examining the impact of APT resistance is either observational in nature or comes from the non-surgical arena, there are two prospective randomized trials that will provide more data on the augmentation of antiplatelet therapy in drug-resistant CABG patients 31, 32 . The former 31 has reached the data analysis stage, while the latter 32 is still recruiting patients. Coronary bypass grafts may be especially vulnerable in the immediate postoperative period, and there is growing evidence that antiplatelet therapy resistance should not be ignored. The first step in individualized tailoring of platelet inhibition should be platelet function testing at approximately 7 days of APT initiation ( Figure 1 ). Once hRPR is recognized, extrinsic factors such as patient non-compliance, drug interactions or suboptimal glucose and cholesterol regulation should be ruled out.
As antiplatelet drug resistance may be a temporary manifestation, one course of action is to re-evaluate the drug effect without changing the current platelet inhibition regime. Within seven days both aspirin and unbolused clopidogrel reach steady state drug levels. We, therefore, recommend repeating platelet function testing 7 days after any PFT result that is outside the desired therapeutic window.
A significant proportion of patients recognized as clopidogrel resistant 24 hours after its institution were found to respond to the drug when re-evaluated at 30 days 33, 34 . Likewise, the proportion of CABG patients found to be aspirin resistant is inversely proportional to the time elapsed between its assessment and the procedure itself 35, 36 . This point again brings into focus the importance of isolating patients with permanent from those with transient postoperative APT resistance. In the event that a follow-up evaluation of platelet function shows persistence of low-responsiveness, different lines of management should be explored.
An effective approach to antiplatelet therapy resistance is to increase the drug dose. In diabetic patients found to be hyporesponsive to 100 mg of aspirin, increasing the dose to 300 mg led to superior platelet inhibition (Platelet Function Analyzer closure time increased from 170±45 to 229±75 seconds, P<0.001) 37 . Increased loading and maintenance doses of clopidogrel have also been found to surmount the resistance to lower-dose therapy 15, 38 .
Doubling the dose of clopidogrel in patients found to be non-responders to 75 mg, effectively inhibited platelets in 60% of patients 39 . Neubauer et al reduced the incidence of clopidogrel resistance from 23.6% to 5% by modification of the administered dose based on an aggregometer-guided algorithm 38 . The conversion of non-responders using this strategy, however, remains unpredictable, which emphasizes the need for re-evaluating the effectiveness of platelet inhibition after the implemented dose change 39 . The BOCLA-plan (Bochum Clopidogrel and Aspirin Plan) incorporating a "test and treat" strategy effectively eliminated aspirin resistance by dose modification and subsequent platelet function testing 40 .
Of the 19.4% patients found to be low-responsive to 100 mg of aspirin, 94.6% were converted to responders by increasing the dose to 300 mg 40 . The remaining 5.4% received effective platelet inhibition by further increasing the dose to 500 mg of aspirin 40 . It is important, however, to acknowledge the potential of high-dose aspirin to worsen endothelial-mediated arterial dilatation 41 . A similar protocol was implemented for the 30.8% of patients found to be resistant to 75 mg of clopidogrel. Increasing the dose to 150 mg, in line with the predefined BOCLA-plan, induced effective platelet inhibition in 69% of previously resistant patients 40 .
Finally, an attractive solution to the problem of hRPR on one platelet inhibitor is to either add a different agent in order to induce an additive effect, or to substitute the original drug altogether. The different mechanisms of platelet inhibition targeted by aspirin and thienopyridines allow for cumulation of their individual anti-aggregational effects. Mannacio et al showed that dAPT effectively overcame single drug resistances, with a subsequent reduction in SVG occlusion (7.4% vs. 13.1%; P=0.04) 5 . Patients randomized to dAPT in the CRYSSA trial experienced similar rates of both minor (2% vs. 1.3%, P=0.5) and major bleeding episodes (1.3% vs. 1.3%, P=1.0) in comparison to the aspirin-monotherapy group 5 .
The safety of dAPT was corroborated by similar chest tube outputs in both treatment arms (115±80 ml in the aspirin group vs. 125±70 ml in the dAPT group (P=0.2)) 5 . The administration of clopidogrel on the background of aspirin therapy in the early postoperative period did not increase the rate of re-exploration or transfusion in a study by Chan et al 42 .
Commonly utilized protocols include starting dAPT when chest tube drainage has been ≤50 46 . A potential problem in interpreting these results is that all-cause mortality was as high as 8.67% in the clopidogrel cohort, which had a mean EuroSCORE of only 3.6±3.2 46 . This caveat is amplified by the fact that EuroSCORE may even overestimate CABG mortality 46, 47 . Nevertheless, prasugrel's highly effective platelet inhibition and very low incidence of non-responsiveness make it a suitable candidate for patients found to be resistant to prior antiplatelet therapy. In the BOCLA study, patients found to be clopidogrel resistant to even an augmented dosing regime, benefited from the addition of prasugrel in achieving the targeted antiplatelet effect 40 .
Ticagrelor is absorbed as an active agent, and is therefore unaffected by the idiosyncrasies of intrinsic biotransformation. 48 . The ticagrelor cohort had a 22% relative reduction in mortality 48 . The incidence of bleeding in the CABG subgroup was not affected by ticagrelor, presumably due to the reversible nature of its P 2 Y 12 inhibition 48 . It has already been shown to be useful in upgrading antiplatelet therapy in patients found to be clopidogrel hyporesponders 49 . In the
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of
Switching Therapies (RESPOND) trial it has provided more uniform and enhanced platelet inhibition in comparison to clopidogrel, practically eliminating on-therapy hRPR 49 .
Prompt induction of platelet inhibition can be achieved with cangrelor. It is a directacting P 2 Y 12 inhibitor that immediately suppresses platelet aggregation 50 . Its effect is quickly reversible upon the drug's discontinuation 50 . Cangrelor's intravenous mode of administration overcomes the variability in enteral absorption and bioavailability seen in patients with acute hemodynamic compromise 51 . Additionally, its very short half-life (3 to 5 minutes) allows for precise bridging of anti-platelet therapy in patients scheduled for elective cardiac surgery, without increasing the risk of major bleeding 52 . While the pharmacokinetic properties of cangrelor make it unsuitable for long-term management of APT resistance, its potential applicability in the acute perioperative setting warrants mentioning. 53 . It increased the risk of bleeding, including intracranial hemorrhage 53 . Exploiting alternative routes of platelet inhibition may be reasonable in patients found to be resistant to the more commonly targeted platelet receptors.
Since the activation of clopidogrel is dependent upon CYP3A4, it stands to reason that pharmacologic induction of this enzyme's metabolic activity may convert clopidogrel nonresponders into responders 54 . Co-administration of rifampin and clopidogrel has been used to explore and prove this concept in healthy volunteers 54 . Whether this approach is of any value in the cardiac surgical population is as of yet unknown.
Discussion
Despite the absence of an all-encompassing method for defining antiplatelet response, there is sufficient evidence to support wider dissemination of tools designed to quantify ontherapy platelet reactivity. Strategies utilizing platelet function tests in order to guide transfusion therapy, reduce bleeding and tailor antiplatelet therapy are gaining momentum in the modern cardiac surgical practice 55, 56 . Platelet aggregability after cardiac surgery is inconsistent over the early postoperative period. Its unpredictable nature stems from the integration of several opposing influences. The effects of postoperative platelet depletion and iatrogenic platelet inhibition are counterbalanced by accelerated post-CPB platelet turnover.
Longitudinal follow-up of platelet reactivity is, therefore, a useful adjunct to standard postoperative protocols aiming to achieve optimal patient outcomes. PFT, platelet function testing; IPA, inhibition of platelet aggregation; hRPR, high residual platelet reactivity; APA, antiplatelet agent; APT, antiplatelet therapy
